Btnl7 Inhibitors
Btnl7 inhibitors are a class of chemical compounds specifically designed to interfere with the activity of the butyrophilin-like 7 (Btnl7) protein. Btnl7 is part of the butyrophilin family, which is structurally related to the immunoglobulin superfamily and is involved in regulating cellular communication, particularly within the immune system. Btnl7 plays a role in modulating interactions between immune cells, influencing processes such as cell activation and signal transduction. Btnl7 inhibitors work by targeting and binding to specific domains on the Btnl7 protein, preventing it from engaging in normal protein-protein interactions. By disrupting these interactions, the inhibitors alter how cells respond to external and internal signals, which can help researchers better understand the functional role of Btnl7 in cellular processes.
The design of Btnl7 inhibitors involves identifying key structural features of the Btnl7 protein that are critical for its function. These features are then used as targets for the development of small molecules, peptides, or biologically derived inhibitors. The inhibitors are optimized for high specificity to Btnl7 to ensure that they do not inadvertently affect other members of the butyrophilin family or unrelated proteins. This specificity is achieved through detailed structural analysis of Btnl7 and the design of inhibitors that can selectively bind to its active or interaction sites. Btnl7 inhibitors are valuable tools for investigating the molecular pathways in which Btnl7 is involved, offering insights into how this protein regulates cellular communication and signal transduction within complex biological systems.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor affecting the MAPK pathway. This indirect modulation influences Btnl7 expression, as p38 MAP kinase is a key regulator of inflammatory responses and cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor blocking the PI3K-AKT pathway. Indirectly, it affects Btnl7 by modulating the PI3K signaling cascade, which plays a role in cell survival, proliferation, and immune responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor blocking the mTOR signaling pathway. It indirectly influences Btnl7 expression by modulating mTOR-dependent cellular processes, impacting immune responses and inflammatory signaling. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
A specific inhibitor of NF-κB signaling. By blocking NF-κB activation, it indirectly influences Btnl7 expression, as NF-κB is involved in the transcriptional regulation of genes related to inflammation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor targeting the MAPK pathway. By suppressing c-Jun N-terminal kinase activity, it indirectly modulates Btnl7 expression, as JNK is implicated in the regulation of key cellular processes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor disrupting the MAPK/ERK pathway. By inhibiting MEK1/2, it indirectly influences Btnl7 expression, as the MAPK/ERK pathway is involved in cellular proliferation and immune responses. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
A JAK2 inhibitor targeting the JAK-STAT pathway. Its indirect influence on Btnl7 involves the inhibition of JAK2, affecting downstream STAT signaling and subsequently altering cellular responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor disrupting the PI3K-AKT pathway. This indirect inhibition impacts Btnl7 by altering the PI3K-mediated signaling cascades that converge on Btnl7 regulation. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
An AKT kinase inhibitor impacting the PI3K-AKT pathway. Its indirect modulation of Btnl7 involves altering AKT signaling, affecting cellular processes related to immune regulation and inflammatory responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
An inhibitor of JAK1 and JAK2. By blocking JAK signaling, it indirectly influences Btnl7 expression, as JAK-STAT pathways play a crucial role in immune responses and inflammatory signaling. | ||||||